Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

BACKGROUND: Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD) of crenezumab and its interaction with monomeric Aβ(1–40) and Aβ(1–42) peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Kenta, Moein, Anita, Bittner, Tobias, Ostrowitzki, Susanne, Lin, Helen, Honigberg, Lee, Jin, Jin Y., Quartino, Angelica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977279/
https://www.ncbi.nlm.nih.gov/pubmed/31969177
http://dx.doi.org/10.1186/s13195-020-0580-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977279/
https://www.ncbi.nlm.nih.gov/pubmed/31969177
http://dx.doi.org/10.1186/s13195-020-0580-2

Ejemplares similares